A Phase 3 interventional study of AVT29 (proposed aflibercept HD biosimilar) and Eylea HD (aflibercept HD) in Diabetic Macular Edema, sponsored by Alvotech Swiss AG. Recruiting at 1 site in Hungary. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-30.
Sponsored by Alvotech Swiss AG · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Macular Edema with a site in Hungary — 2 open to participants now, 5 under way, 3 of them phase 3. Macular Edema · Hungary.
Among the 39 studies in Macular Edema with a site in Hungary, this one is the 26th largest by planned enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2026, is one of 28 in phase 3, and was the 39th registered.
759 studies on the registry are indexed under Macular Edema; 66 are open to participants now.
Browse Macular Edema studies →2 of the 39 studies in Macular Edema with a site in Hungary are open now. Recruiting first, the newest first:
Boehringer Ingelheim · Sites in Hungary, United States, China and 6 more countries
Ages 18+
A study can be open while its sites in Hungary have not opened yet or have stopped. Only those recruiting at a site in Hungary →
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 7 · Phase 3 29 · Phase 4 2
First in 2005; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 256 is above the median of 56 across 587 interventional studies indexed under Macular Edema.
Median enrollment 406 across the 37 interventional studies, 463 across the 2 observational. Of the 32 that completed or were terminated, 29 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 39 have an industry lead sponsor. The 10 most frequent:
Alvotech Swiss AG is the lead sponsor of 20 studies on the registry; 2 are open to participants now.
Alvotech Swiss AG has 1 study filed under Macular Edema — fewer than ten, so there is no comparison to draw.
3 of the studies in Macular Edema with a site in Hungary that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07489131Phase 3Alvotech Swiss AGClinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular Edema | 2027-07 |
| NCT07449923Phase 3EyePoint Pharmaceuticals, Inc.CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME | 2027-10 |
| NCT06680817Hoffmann-La RocheA Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study) | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 39 studies in Macular Edema with a site in Hungary, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Randomized, Double-masked, Parallel-group, Multicenter Clinical Study to Evaluate the Efficacy and Safety of AVT29 Compared with Eylea HD in Participants with Diabetic Macular Edema.
Main Inclusion Criteria:
Main Exclusion Criteria:
Participants will receive 1 IVT injection of AVT29 at baseline and every 4 weeks for 2 consecutive monthly visits (at Week 4 and Week 8), followed by 1 IVT injection every 8 to 16 weeks based on DRM criteria through study completion.
Drug: AVT29 (proposed aflibercept HD biosimilar)
Participants will receive 1 IVT injection of Eylea HD at baseline and every 4 weeks for 2 consecutive monthly visits (at Week 4 and Week 8), followed by 1 IVT injection every 8 to 16 weeks based on DRM criteria through study completion.
Drug: Eylea HD (aflibercept HD)
Patients will receive IVT injections of AVT29
Patients will receive IVT injections of Eylea HD
Change from baseline to Week 8 in BCVA as measured by ETDRS letter score
Time frame: week 8
Started Apr 2026 (actual). Primary completion is estimated for Jul 2027, 15 months after the start.
Of 52 industry-sponsored phase 3 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 33. This study's planned 15 months is below that.
Counting every sponsor, half of 65 studies reached it within 25 months; a quarter within 18 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Alvotech Swiss AG